Tin tức & Cập nhật

In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.

Treatment intensification is needed in around one-third of biologic-naïve patients with inflammatory bowel disease (IBD) who had received initial antitumour necrosis factor α (anti-TNFα) medication, a recent study has found.

The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.

Four cycles of neoadjuvant chemotherapy (NACT) results in better pathological response and survival than three NACT cycles in patients with muscle invasive bladder cancer, reveals a recent study.

Conventional treatment options for chronic constipation (CC) are not effective enough to improve symptoms or satisfaction among patients, results of an internet survey in Japan have shown.

Induction with ixazomib-based regimens appear to be insufficient for older patients newly diagnosed multiple myeloma who are ineligible for transplantation, achieving an unsatisfactory progression-free survival (PFS) rate, reports a recent study.